Tools   Select Another Resource Report Type

https://www.corengi.com/

A comprehensive, free, and interactive platform to help individuals discover more about clinical trials that may be appropriate for them for a variety of diseases. The platform allows stakeholders within the clinical trials community (investigators, site personnel, sponsors, and disease advocates) to engage with potential enrollees and educate them about specific clinical trials. They have identified some of the most commonly used criteria for the clinical trials in each disease. Using these criteria, they developed a questionnaire for a single disease. Then, looking at just those questions, they can start to get a sense of which clinical trials might be appropriate for a particular person which is a helpful to start to narrow down the list of potentially appropriate trials. All clinical trials that are posted on www.clinicaltrials.gov for the diseases that Corengi covers will be on the website.

Proper citation: Corengi (RRID:SCR_003942) Copy   

•   Source: SciCrunch Registry

http://www.almirall.com/

A pharmaceutical company committed to provide valuable medicines through their own R&D efforts, licenses and collaborations. Through seeking innovative medicines they aim to become a relevant player in respiratory and dermatology diseases with also a strong interest in gastroenterology and pain. The company is headquartered in Barcelona, Spain, and has 14 affiliates in Europe and North America and trading capacity in 22 countries.

Proper citation: Almirall (RRID:SCR_003947) Copy   

•   Source: SciCrunch Registry

http://www.simulations-plus.com/

Commercial developer of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) and Physiologically-Based Pharmacokinetic (PBPK) modeling and simulation software for the pharmaceutical and biotechnology, industrial chemical, cosmetic, herbicide, and food ingredient industries. Their software allows pharmaceutical scientists to predict certain key potential endpoints and dynamics, in silico, thereby reducing research & development costs and helping clients make better projects decisions sooner. Consulting services: Their team of highly-skilled scientists is available to assist with your discovery and development activities on a project-by-project basis. They now offer expanded pharmacodynamic modeling services, NONMEM analysis, and regulatory report writing assistance. Their ultimate goal is to develop tools and systems which bridge PBPK modeling with clinical trial data analysis. Training workshops & User Groups: they offer hands-on introductory and advanced training workshops in the United States, Europe, and Asia throughout the year.

Proper citation: Simulations Plus (RRID:SCR_003946) Copy   

•   Source: SciCrunch Registry

http://www.qualissima.com/en/

A Research as a Service (RaaS) Company founded by a Clinical Pharmacologist and Neuropsychiatrist that offers to its partners (health products industries and public research), 3 platforms: * Clinical research (CRO and SMO) * Scientific & regulatory consulting * Online surveys (Web portal) Their Research & Development profile allows them to propose innovative concepts such as : * Patient-Leader studies * Translational research studies (fMRI, innovative biomarkers, modeling, ...) * Behavioral parameters as biomarkers studies Qualissima also proposes proof of concept studies, proof of activities studies, medical devices studies and observational studies.

Proper citation: Qualissima (RRID:SCR_003941) Copy   

•   Source: SciCrunch Registry

http://wiki.geneontology.org/index.php/GOlr

A public Solr index for the Gene Ontology. This index will replace some of the query functionality for GOOSE as well as become the new backend for AmiGO 2 and other services.

Proper citation: GOlr (RRID:SCR_003939) Copy   

•   Source: SciCrunch Registry

https://www.myast.org/

An organization of transplant professionals dedicated to advancing the field of transplantation and improving patient care by promoting research, education, advocacy, and organ donation.

Proper citation: American Society of Transplantation (RRID:SCR_003970) Copy   

•   Source: SciCrunch Registry

https://www.bigtencrc.org/

A consortium that aims to transform cancer research through collaborative oncology trials that leverage the scientific and clinical expertise of the Big Ten universities. The goal is to align the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise. The clinical trials that will be developed will be linked to molecular diagnostics, enabling researchers to understand what drives the cancers to grow and what might be done to stop them from growing. The consortium also leverages geographical locations and existing relationships among the cancer centers. One of the consortium's goals is to harmonize contracts and scientific review processes to expedite clinical trials. The consortium will only focus on phase 0 to II trials because larger trials - even a randomized phase II trial - are difficult to conduct at a single cancer center.

Proper citation: Big Ten Cancer Research Consortium (RRID:SCR_004025) Copy   

•   Source: SciCrunch Registry

http://www.asclepia.com/

Commercial organization that offers medicinal chemistry services and consulting consisting of the combination of structure based drug design and computational chemistry with multi-disciplinary expertise. A proven track record exists in the identification and the delivery of successful drug candidates. They offer solutions within small molecule drug discovery and outsourcing project management.

Proper citation: Asclepia MedChem Solutions (RRID:SCR_004023) Copy   

•   Source: SciCrunch Registry

http://www.arborresearch.org/

A not-for-profit research organization committed to improve patient care through research that shapes medical policies and practice. In particular, they conduct health outcomes research on chronic disease and end-stage organ failure, with expertise in biostatistical analysis, clinical practice, health economics, public policy, database management and integration, and project coordination. Through research projects that are national and global in scope, their scientific collaborations provide valuable and timely information to the worldwide health care community. They are a leader in interdisciplinary health outcomes and policy research focused on reducing the health and economic burden of chronic diseases and improving the delivery of care.

Proper citation: Arbor Research Collaborative for Health (RRID:SCR_003972) Copy   

•   Source: SciCrunch Registry

http://danstem.ku.dk/

Center consisting of 9 research groups who all address basic questions in stem cell and developmental biology with the overall aim of developing new stem cell-based therapeutic approaches for diabetes and cancer. DanStem comprises two sections: * The Novo Nordisk Foundation Section for Basic Stem Cell Biology (BasicStem) * The Section for Strategic Translational Stem Cell Research and Therapy (TransStem) DanStem was established as a result of a series of international recruitments coupled with internationally recognized research groups focused on insulin producing beta cells and cancer research already located at the University of Copenhagen. They all have well-established, international collaborations and actively participate in several international scientific consortia. DanStem is also active in training undergraduates, PhD students and postdocs.

Proper citation: DanStem (RRID:SCR_004021) Copy   

•   Source: SciCrunch Registry

http://www.mcewencentre.com/

Center aiming to be a catalyst for regenerative medicine by facilitating collaboration, supporting research, and promoting awareness of the field. The center includes 15 scientists at five Toronto hospitals, as well as the University of Toronto, currently working to accelerate the development of more effective treatments for conditions such as heart disease, diabetes, respiratory disease and spinal cord injury. They collaborate with many other research institutions throughout North America, Europe and the Asia / Pacific region. The research is powered by a team of recent doctoral graduates recruited from around the world that are selected through a competitive process. They are a critical tool for supporting the work of McEwen Centre, allowing them to find medical breakthroughs faster.

Proper citation: McEwen Centre for Regenerative Medicine (RRID:SCR_004020) Copy   

•   Source: SciCrunch Registry

http://www.annanurse.org/

Non-profit professional association that represents nurses who work in all areas of nephrology including hemodialysis, chronic kidney disease, peritoneal dialysis, acute care, and transplantation. Most members work in freestanding dialysis units, hospital outpatient units, and hospital inpatient units. ANNA develops and updates standards of clinical practice, educates practitioners, stimulates and supports research, disseminates knowledge and new ideas, promotes interdisciplinary communication and cooperation, and monitors and addresses issues encompassing the breadth of practice of nephrology nursing.

Proper citation: American Nephrology Nurses Association (RRID:SCR_003966) Copy   

•   Source: SciCrunch Registry

https://www.aakp.org/

Association of kidney patients focused on patient-centered education, advocacy and community. They share educational pieces covering every level of kidney disease, advocate for improved access to high-quality health care through regulatory and legislative reform at the federal level, and make an effort to bring kidney patients together to promote community, conversations and to seek out services that help maximize patients'' everyday lives.

Proper citation: American Association of Kidney Patients (RRID:SCR_003965) Copy   

•   Source: SciCrunch Registry

http://www.solvobiotech.com/

Commercial organization that is a worldwide provider of drug transporter technology, assays and reagents. Leveraging their expertise in efflux and uptake transporters, they generate quality reports for submission to FDA / EMA. From small molecules to protein therapeutics, SOLVO can test all transporter needs. Drug transporter Services and Products include: * Over 100 solutions for a wide range of transporters * Uptake transporter assays * Efflux transporter assays in cellular and membrane-based models * Transporter Consultancy Services * FDA- and EMA-ready reports * Ready-to-use Kits * In vitro and in vivo methods for studying transporters in the BBB, intestine, liver and kidney * Custom assay development

Proper citation: SOLVO Biotechnology (RRID:SCR_003964) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT01211678

A consortium evaluating a new biomarker screening test that might help identify patients with rheumatoid arthritis (RA) who are unlikely to benefit from anti-tumor necrosis factor-alpha (TNFalpha) medications. BATTER-UP will enroll around 1,000 patients being treated by one of several marketed anti-TNF RA drugs: Enbrel, Remicade, Humira, Simponi, or Cimzia. Through data analyses and predictive response modeling, the consortium aims to better understand which patients with RA will derive the greatest benefit from TNF inhibitors. The investigators in this observational study will attempt to validate an 8-gene biomarker set based on work by Biogen Idec researchers as likely to predict anti-TNF responsiveness in patients with RA. In preliminary results, the 8-gene biomarker set predicted with 89% accuracy individuals who did not reach European League Against Rheumatism (EULAR) Disease Activity Score (DAS)-28 good response after 14 weeks of treatment. The 8 genes included in the screen are CLTB, MXRA7, CXorf52, COL4A3BP, YIPF6, FAM44A, SFRS2, and PGK1. Biological samples and clinical outcome information will be used to confirm and extend the utility of previously published biomarkers that can predict response to anti-TNF agents. These data may also generate new hypotheses for further testing. The BATTER-UP samples and data will be established as a reference set for investigation of personalized medicine in RA. The study will be a resource of DNA and other biological materials that can be investigated for biomarkers in the future as new technologies arise.

Proper citation: Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis - Unresponsive Populations (RRID:SCR_004019) Copy   

•   Source: SciCrunch Registry

http://sourceforge.net/projects/seqexpress/

A cross-platform software that estimates gene/isoform expression level via mRNA-Seq data. SeqExpress exams the Sequencing bias in mRNA-Seq and correct it to get more accurate estimation.

Proper citation: SeqExpress (RRID:SCR_004013) Copy   

•   Source: SciCrunch Registry

http://datacatalog.med.nyu.edu/

A searchable data catalog that facilitates researchers'' access to large datasets available either publicly or through institutional or individual licensing. Dataset records include information about the content of the dataset, how to access the dataset, and local experts within NYULMC and NYU to assist in the use of these datasets. The data catalog will expand to include internally generated datasets from NYULMC and NYU in the near future. Use the contact form if you are interested in submitting a dataset to the data catalog.

Proper citation: NYU Data Catalog (RRID:SCR_004012) Copy   

•   Source: SciCrunch Registry

http://www.westonfoundation.org/

Foundation that gives grants in Canada for the benefit of Canadians and directs its resources to specific organizations in Education, Land Conservation and Science in Canada''s North. In addition, it provides funds to further Canada''s research in neuroscience. These programs are director-initiated and the Foundation therefore does not accept applications for funding. By law, the Foundation is only able to support Canadian charities that are registered with the Canadian Revenue Agency. These charities must have a CRA charitable number and offer programs benefiting Canadians in Canada.

Proper citation: W. Garfield Weston Foundation (RRID:SCR_004017) Copy   

•   Source: SciCrunch Registry

http://www.cxrbiosciences.com/

Commercial organization that provides preclinical services and expertise, specializing in investigative toxicology, exploratory and discovery toxicology, metabolism and pharmacokinetics. CXR Biosciences is now Concept Life Sciences.

Proper citation: CXR Biosciences (RRID:SCR_003961) Copy   

•   Source: SciCrunch Registry

http://www.alz.org/research/alzheimers_grants/biomarkers-across.asp

Consortium that launched a Request for Applications (RFA) to stimulate analyses across the Alzheimer's disease (AD) and Parkinson's disease (PD) research enterprises to engage in further data analysis of existing cohorts, including, but not limited to, biomarker discovery, standardization of assays, genetic profiles, and imaging modalities. The RFA aims to build on existing momentum to leverage similar activities and increase impact across the neurodegenerative disease spectrum. It also builds on recent evidence suggesting substantial overlap between AD, PD, and other neurodegenerative diseases pathologically, but also potentially biologically. The RFA is designed to enable preliminary pilot research or proof-of-principle studies utilizing data and/or samples from two large biomarker studies, the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Parkinson's Progression Markers Initiative (PPMI), in order to garner further research support from other funding agencies. Application Deadline: March 19, 2014. Efforts under BAND include studies that: * analyze datasets to test hypotheses related to aging and neurodegenerative disorders; * seek to identify panels or pathways that may play a role in disease mechanisms, such as around inflammation; * pursue shared or disparate biochemical markers of disease risk, onset or progression; * assess potential commonalities across the disease spectrum, including around other neurological disorders such as Lewy body dementia. Recent data reported at the 2013 Alzheimer's Association's International Conference stimulated discussion in the research community about the possible cross talk between AD and PD. For example, underlying pathologies / biomarkers, such as cerebrospinal fluid (CSF) alpha-synuclein, have been measured in the sample sets collected for both diseases to help understand similarities and differences in these diseases. Furthermore, similar imaging modalities, such as MRI and PET, are being employed to interrogate changes that occur with disease progression. As therapeutic approaches are developed that may be disease-modifying for several neurodegenerative diseases, stratification of clinical trial populations based on biomarker profiles may increase the probability of success in demonstrating a beneficial effect.

Proper citation: Biomarkers Across Neurodegenerative Diseases (RRID:SCR_004015) Copy   

•   Source: SciCrunch Registry